ArticleJHEP reports : innovation in hepatology2025
Towards precision medicine strategies using plasma proteomic profiling for suspected gallbladder cancer: A pilot study.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review.Antibodies (Basel, Switzerland) · 2026Review
- Clinical and Molecular Signatures of Gallbladder Lesions: Insights into Metabolic and Inflammatory Pathways.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Currently, preoperative diagnostic methods that can distinguish cancer from benign disease of the gallbladder are insufficient, and several surgical resections can be avoided if the pathology is known prior to surgery. This study aimed to assess whether preoperative plasma proteins can distinguish gallbladder cancer (GBC) from cholecystitis, with the main goal of identifying proteins for multivariate description of the postoperative diagnosis, before surgery. Methods: Samples from 82 individuals with suspected GBC who underwent bisegmentectomy and lymphadenectomy at Karolinska University Hospital between 2009 and 2020 were included in this retrospective, observational, single-center study. Preoperative plasma samples were analyzed using a 7,500 proteomics panel from SomaScan®. High-dimensional statistical methods including machine learning regularization, were used to analyze the data. Results: In our study, we identified and characterized a panel of 651 proteins that exhibited differential expression between GBC and cholecystitis. Through multivariate analysis, we demonstrated that circulating proteomics data provide valuable insights for diagnosing GBC before surgical intervention. Notably, we identified a subset of eight plasma proteins (PAHX, CD8A, HRG, CRIS2, Dynactin subunit 2, AT2A3, CSTN2, and DEPP) that effectively differentiated GBC from cholecystitis with a diagnostic accuracy of 94% when validated on a test set. These findings hold potential for clinical validation and could significantly aid in preoperative decision-making when GBC is suspected. Conclusions: Our findings demonstrate that the preoperative assessment of plasma proteins can accurately differentiate cholecystitis from malignancy, supporting the potential development of a noninvasive test to assist preoperative decision-making when GBC is suspected. Impact and implications: This study highlights the potential of plasma proteomic profiling to significantly improve the preoperative diagnostic accuracy of gallbladder cancer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.